8-K: BioAtla Secures Conditional Nasdaq Listing Extension

BioAtla, Inc. has received conditional approval from the Nasdaq Hearing Panel to maintain its listing, requiring transfer to The Nasdaq Capital Market and compliance with equity and bid price requirements by early 2026.

Summary

• BioAtla, Inc. (the Company) previously received a delist determination from Nasdaq on August 6, 2025, for not satisfying the Minimum Bid Price Requirement (Nasdaq Listing Rule 5450(a)(1)) and the Minimum Stockholders Equity Requirement (Nasdaq Listing Rule 5450(b)(1)(A)).
• The Company appealed this determination and presented a Compliance Plan to the Nasdaq Hearing Panel on September 9, 2025, which included expected near-term corporate events, clinical developments, planned data readouts, and potential strategic partnerships.
• On September 16, 2025, the Panel granted the Company's request for continued listing on Nasdaq, subject to specific conditions.
• Conditions include filing an application to transfer to The Nasdaq Capital Market on or before September 26, 2025, demonstrating compliance with the Minimum Stockholders Equity Requirement on or before December 31, 2025, and demonstrating compliance with the Minimum Bid Price Requirement on or before February 2, 2026.
• The Company submitted its application to transfer to The Nasdaq Capital Market on September 18, 2025.
• Management believes it will be able to demonstrate compliance with both the Minimum Stockholders Equity Requirement and the Minimum Bid Price Requirement prior to their respective deadlines, though no assurance can be given.

Sentiment

Score: 6

Explanation: While the company avoided immediate delisting, which is a positive, the underlying issues of not meeting Nasdaq's requirements and the need to transfer markets persist. The future compliance is not assured, and significant risks remain, including the need for additional funding and going concern doubts.

Positives

• The Nasdaq Hearing Panel granted the Company's request for continued listing, preventing an immediate delisting from Nasdaq.
• The Company has a clear Compliance Plan aligned with its business objectives, including expected clinical developments and potential strategic partnerships, to regain compliance.
• Management expresses belief in its ability to demonstrate compliance with both Nasdaq requirements by the specified deadlines.

Negatives

• The Company initially failed to satisfy Nasdaq's Minimum Bid Price Requirement and Minimum Stockholders Equity Requirement, leading to a delist determination.
• The Company is required to transfer from The Nasdaq Global Market to The Nasdaq Capital Market, which may imply a lower market tier and potentially reduced visibility or liquidity.
• Compliance with the Nasdaq requirements by the specified deadlines is not assured, as explicitly stated by management.

Risks

• Factors that raise substantial doubt about the Company's ability to continue as a going concern.
• The need for additional funding to continue development of the Company's CAB technology platform and CAB product candidates.
• Potential delays in clinical and preclinical trials.
• Uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data.
• Whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies.
• The Company's dependence on the success of its CAB technology platform.
• The Company's ability to enroll patients in its ongoing and future clinical trials.
• The successful selection and prioritization of assets to focus development on selected product candidates and indications.
• The Company's ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships.
• The Company's reliance on third parties for the manufacture and supply of its product candidates for clinical trials.
• The Company's reliance on third parties to conduct its clinical trials and some aspects of its research and preclinical testing.
• Potential adverse impacts due to geopolitical or macroeconomic events outside of the Company's control, including health epidemics or pandemics.

Future Outlook

Management believes it will be able to demonstrate compliance with both the Minimum Stockholders Equity Requirement by December 31, 2025, and the Minimum Bid Price Requirement by February 2, 2026. The Compliance Plan includes expected near-term corporate events, clinical developments, planned data readouts, and potential strategic partnerships.

Management Comments

• "The Company believes that it will be able to demonstrate its compliance with the Minimum Stockholders Equity Requirement prior to the December 31, 2025 deadline and that it will be able to demonstrate its compliance with the Minimum Bid Price Requirement prior to the February 2, 2026 deadline, although no such assurance can be given."

Industry Context

The biotech industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often face challenges in maintaining sufficient capital and market valuation, especially those in clinical stages. Nasdaq's listing requirements ensure a certain level of financial health and market interest, and non-compliance can be a common issue for smaller, development-stage biotech firms. The need to transfer to The Nasdaq Capital Market indicates a move to a market tier with less stringent listing requirements, a common occurrence for companies facing these challenges.

Stakeholder Impact

• Shareholders: Continued listing on Nasdaq (albeit a different market) provides liquidity and visibility, but the underlying financial challenges and compliance risks could impact share value. The transfer to The Nasdaq Capital Market might be perceived negatively.
• Employees: Continued operations and listing may provide stability, but the 'going concern' risk could create uncertainty regarding job security.
• Partners/Creditors: The ability to maintain listing and progress clinical developments could reassure partners and creditors, but financial instability remains a concern.

Next Steps

• Demonstrate compliance with the Minimum Stockholders Equity Requirement on or before December 31, 2025.
• Demonstrate compliance with the Minimum Bid Price Requirement on or before February 2, 2026.

Key Dates

Recommendation

The company successfully appealed its delisting, which is a positive development preventing immediate loss of exchange listing. However, the underlying issues that led to the delisting notice (failure to meet minimum bid price and stockholders' equity) persist, and compliance by the new deadlines is not assured. The transfer to The Nasdaq Capital Market, while allowing continued listing, may be viewed as a step down. Given the significant risks outlined, including going concern doubts and the need for additional funding, a 'hold' recommendation is appropriate. Investors should monitor the company's progress towards meeting the compliance deadlines and its strategic partnership efforts.

Keywords

BioAtla, Nasdaq, delisting, listing compliance, minimum bid price, stockholders equity, biotech, pharmaceutical, clinical trials, strategic partnerships, 8-K